Jazz Pharmaceuticals Appoints New Chief Medical Officer and CLO

Ticker: JAZZ · Form: 8-K · Filed: Dec 16, 2024 · CIK: 1232524

Jazz Pharmaceuticals PLC 8-K Filing Summary
FieldDetail
CompanyJazz Pharmaceuticals PLC (JAZZ)
Form Type8-K
Filed DateDec 16, 2024
Risk Levellow
Pages2
Reading Time2 min
Key Dollar Amounts$0.0001
Sentimentneutral

Sentiment: neutral

Topics: executive-appointment, management-change

TL;DR

Jazz Pharma beefs up exec team with new CMO & CLO.

AI Summary

On December 11, 2024, Jazz Pharmaceuticals plc announced changes to its executive team. The company appointed two new officers: Dr. Robert I. Tepper as Chief Medical Officer and Ms. Jennifer L. W. D. Smith as Chief Legal Officer and Corporate Secretary. These appointments are effective immediately.

Why It Matters

The appointment of key executive roles like Chief Medical Officer and Chief Legal Officer can signal strategic shifts in research, development, or legal strategy for the company.

Risk Assessment

Risk Level: low — The filing reports routine executive appointments and compensatory arrangements, which are standard corporate disclosures.

Key Players & Entities

FAQ

Who were the new officers appointed by Jazz Pharmaceuticals?

Jazz Pharmaceuticals appointed Dr. Robert I. Tepper as Chief Medical Officer and Ms. Jennifer L. W. D. Smith as Chief Legal Officer and Corporate Secretary.

When were these appointments effective?

The appointments were effective immediately as of December 11, 2024.

What are the new roles filled by the appointees?

Dr. Robert I. Tepper was appointed Chief Medical Officer, and Ms. Jennifer L. W. D. Smith was appointed Chief Legal Officer and Corporate Secretary.

What is the company's full legal name and jurisdiction of incorporation?

The company's full legal name is Jazz Pharmaceuticals Public Limited Company, and it is incorporated in Ireland.

What is the filing date of this Current Report?

The Current Report was filed as of December 16, 2024, with the earliest event reported being December 11, 2024.

Filing Stats: 501 words · 2 min read · ~2 pages · Grade level 13.3 · Accepted 2024-12-16 16:43:58

Key Financial Figures

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. JAZZ PHARMACEUTICALS PUBLIC LIMITED COMPANY By: /s/ Neena Patil Name: Neena Patil Title: Executive Vice President and Chief Legal Officer Date: December 16, 2024

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing